CLEOPATTRA: Effects of NNC6019-0001 Versus Placebo on Cardiovascular Outcomes in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Latest Information Update: 21 Oct 2025
At a glance
- Drugs Coramitug (Primary)
- Indications Heart failure
- Focus Registrational; Therapeutic Use
- Acronyms CLEOPATTRA
- Sponsors Novo Nordisk
Most Recent Events
- 16 Oct 2025 Status changed from not yet recruiting to recruiting.
- 09 Oct 2025 New trial record